MELK — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL528368	1.00	20/20
SCHEMBL528473	1.00	20/20
SCHEMBL528480	1.00	20/20
SCHEMBL528659	1.00	20/20
SCHEMBL528699	1.00	20/20
SCHEMBL528707	1.00	20/20
SCHEMBL528310	0.86	20/20
SCHEMBL528655	0.86	20/20
SCHEMBL528656	0.86	20/20
SCHEMBL528333	0.78	20/20
SCHEMBL528533	0.78	20/20
SCHEMBL528663	0.76	20/20
SCHEMBL528664	0.76	20/20
SCHEMBL528577	0.75	20/20
SCHEMBL528701	0.74	20/20
SCHEMBL528721	0.74	20/20
SCHEMBL528406	0.73	20/20
SCHEMBL528700	0.70	20/20
SCHEMBL528616	0.70	20/20
SCHEMBL528315	0.69	20/20

Clinical trials — most relevant to MELK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)	PHASE2	COMPLETED
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer	PHASE1/PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Safety Study of Preimplantation Factor (PIF-1) to Treat Acute Steroid-Resistant Graft-Versus-Host Disease (GVHD)	PHASE1	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Itacitinib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Muscle Wasting in Cancer (MWIC)	nan	COMPLETED
Effects of Contact Restrictions During the COVID-19 Pandemic on Newborns and Their Parents	nan	COMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Leucine Requirements During Pregnancy	nan	RECRUITING
Scottish Advanced Fetal Research Study	nan	RECRUITING
EKLF Gene Expression in β-thalassemia	nan	NOT_YET_RECRUITING
CircularRNA-microRNA-mRNA Regulatory Axis in IVF	nan	NOT_YET_RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients	nan	NOT_YET_RECRUITING
A Comparison of p53-induced Genes Activation in Patients With and Without Acute Myocardial Infarction	nan	COMPLETED
miRNA-452 in Patients With Preeclampsia and Its Correlation With MMP-9	nan	COMPLETED
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes	nan	UNKNOWN
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Developing Derived Induced Pluripotent Stem Cells as a Model to Understand Imprinted Disorders	nan	ENROLLING_BY_INVITATION
Characterization of Methylation Pattern in Human Germ Cells of Patients Undergoing ICSI Treatment	nan	COMPLETED
Placenta Development Study	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MELK binder may also engage these)

Protein	Name	Similarity
Q28GW8	—	1.000	Q28GW8 →
Q91821	—	1.000	Q91821 →
Q61846	—	0.999	Q61846 →
F1QGZ6	—	0.997	F1QGZ6 →
PLK2	Serine/threonine-protein kinase PLK2	0.987	landscape →
Q69Z98	—	0.986	Q69Z98 →
Q9R012	—	0.986	Q9R012 →
Q5R4L1	—	0.986	Q5R4L1 →
BRSK2	Serine/threonine-protein kinase BRSK2	0.985	landscape →
Q61083	—	0.985	Q61083 →
P62205	—	0.984	P62205 →
Q852Q2	—	0.984	Q852Q2 →
O54785	—	0.984	O54785 →
P53351	—	0.984	P53351 →
Q61084	—	0.984	Q61084 →
MAP3K3	Mitogen-activated protein kinase kinase kinase 3	0.983	landscape →
Q6DD21	—	0.982	Q6DD21 →
Q38997	—	0.982	Q38997 →
LIMK2	LIM domain kinase 2	0.981	landscape →
Q8VDY4	—	0.981	Q8VDY4 →
CHEK1	Serine/threonine-protein kinase Chk1	0.981	landscape →
Q8BG48	—	0.981	Q8BG48 →
O35280	—	0.981	O35280 →
Q9Z265	—	0.981	Q9Z265 →
Q6DE87	—	0.981	Q6DE87 →
MAP3K2	Mitogen-activated protein kinase kinase kinase 2	0.981	landscape →
Q6ZWJ1	—	0.981	Q6ZWJ1 →
Q6PJI9	—	0.980	Q6PJI9 →
O14830	—	0.980	O14830 →
Q8TDW5	—	0.980	Q8TDW5 →